drugset / Trial / NCT05105295
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV Infected
Phase 4
Unknown
400 enrolled
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd. · collabZhejiang Provincial Center for Disease Control and Prevention · collab
NaSingle-groupOpen-labelPrevention
Summary
Evaluation of immunogenicity, safety and persistence of the subjects with HIV infected received the third dose of inactivated COVID-19 vaccine .
Timeline
- Start
- 2021-12
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CoronaVac | Vaccine | — | — |